Alvotech and Finesse Announce Cooperation
Alvotech, a company in the field of biopharmaceuticals, and Finesse Solutions announced that they have entered into a partnership. This alliance will provide Alvotech with scalable, flexible and cost efficient manufacturing and laboratory technology through the Finesse Smartfactory GMP manufacturing platform suite. It is a single‐use cGMP biomanufacturing capacity, which will allow Alvotech to expand its biosimilars business of monoclonal antibody molecules. Finesse's customers will benefit from access to Alvogen's commercial, FDA approved, biomanufacturing facility.
Commenting, Dr. Andreas Herrmann, CEO of Alvotech, said: "This partnership allows us to leverage Finesse's single‐use bio-manufacturing automation platform, combining best-of-breed bio-process equipment from upstream through downstream. This strategic relationship provides us with much‐needed additional manufacturing capacity and scale-up capabilities which will allow us to expedite our ambitions to become a global leader in the high-growth biopharmaceutical industry. The first manufacturing suite will be in place by the end of 2015."
Dr. Barbara Paldus, CEO of Finesse, added: "Alvotech is capitalizing on the extraordinary flexibility afforded by SmartFactory, and together we will be able to implement cutting-edge, innovative solutions for established and development-stage biosimilars processes. The Alvotech facility will showcase our latest Smart Technologies in process control, batch automation and data management. This partnership will also provide us with an important path to offer full‐scale commercial manufacturing to our customers,"